The estimated Net Worth of Cynthia Collins is at least $14.9 millió dollars as of 21 May 2024. Ms. Collins owns over 8,663 units of Editas Medicine Inc stock worth over $91,329 and over the last 6 years she sold EDIT stock worth over $290,688. In addition, she makes $14,489,700 as President, Chief Executive Officer és Director at Editas Medicine Inc.
Cynthia has made over 6 trades of the Editas Medicine Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently she exercised 8,663 units of EDIT stock worth $32,746 on 21 May 2024.
The largest trade she's ever made was exercising 9,067 units of Editas Medicine Inc stock on 17 May 2023 worth over $34,273. On average, Cynthia trades about 1,455 units every 72 days since 2018. As of 21 May 2024 she still owns at least 24,161 units of Editas Medicine Inc stock.
You can see the complete history of Ms. Collins stock trades at the bottom of the page.
Cynthia L. Collins serves as President, Chief Executive Officer, Director of the Company. Ms. Collins previously served as the Chief Executive Officer of Human Longevity, Inc. ("Human Longevity"), a genomics company, from January 2017 to December 2017. Prior to joining Human Longevity, Ms. Collins served as the Chief Executive Officer and GM of the Cell Therapy and Lab Businesses of GE Healthcare Life Sciences, a division of General Electric Company ("GE Healthcare"), a global digital industrial company, from April 2015 to December 2016, and as CEO of Clarient Diagnostics, Inc., a division of GE Healthcare, from October 2013 to April 2015. Prior to GE Healthcare, she served as Chief Executive Officer and director of GenVec, Inc., a public biopharmaceutical company, from May 2012 to September 2013 and as Group Vice President, Cellular Analysis of Beckman Coulter, a global supplier of diagnostic solutions, from 2007 to 2011. Ms. Collins also serves on the board of directors of Triumvira Immunologics, Inc., a private biotechnology company, since April 2018, DermTech, Inc., a public diagnostics company, since May 2018 and Biocare Medical, LLC, a private instrumentation and reagents company, since September 2018. Ms. Collins also served on the board of directors of Provista Dx, a private diagnostics company, from March 2018 until December 2018 and Cavidi AB, a private research and clinical diagnostics company, from March 2018 until June 2019. Ms. Collins received a BS, Microbiology from the University of Illinois, Urbana and an MBA from The University of Chicago Booth School of Business.
As the President, Chief Executive Officer és Director of Editas Medicine Inc, the total compensation of Cynthia Collins at Editas Medicine Inc is $14,489,700. There are no executives at Editas Medicine Inc getting paid more.
Cynthia Collins is 62, she's been the President, Chief Executive Officer és Director of Editas Medicine Inc since 2019. There are 4 older and 12 younger executives at Editas Medicine Inc. The oldest executive at Editas Medicine Inc is Dr. George McDonald Church Ph.D., 67, who is the Co-Founder & Scientific Advisory Board Member.
Cynthia's mailing address filed with the SEC is C/O POSEIDA THERAPEUTICS, INC., 9390 TOWNE CENTER DRIVE SUITE 200, SAN DIEGO, CA, 92121.
Over the last 9 years, insiders at Editas Medicine Inc have traded over $73,429,036 worth of Editas Medicine Inc stock and bought 241,700 units worth $4,697,822 . The most active insiders traders include Andrew A. F. Hack, Kevin P Starr és Kevin Bitterman. On average, Editas Medicine Inc executives and independent directors trade stock every 22 days with the average trade being worth of $126,770. The most recent stock trade was executed by Baisong Mei on 4 September 2024, trading 518 units of EDIT stock currently worth $1,772.
unlocking the promise of genome editing to deliver life-changing medicines. editas medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.
Editas Medicine Inc executives and other stock owners filed with the SEC include: